AmTrust International has completed its acquisition of Big Wakam, the holding company that controls French insurer Wakam SA and Wakam UK. The deal restores the solvency Wakam needs to write new contracts and renew existing policies. The price was not disclosed. French outlet News Assurances Pro reported a symbolic sum and a "return to better fortune" clause. The deal includes an immediate injection of about €100 million into Wakam SA, required by French supervisor ACPR. ACPR had barred Wakam SA from writing or renewing contracts, judging its recovery plan insufficient. Wakam SA ended 2025 with a solvency capital requirement coverage ratio of 66%. Chief executive Olivier Jaillon, who holds 14%, is expected to stay on.

Bermuda-based Compre extends Renewable LPT agreement with French insurer Wakam. Compre, an international speciality reinsurance group based in Bermuda, has renewed its Renewable Loss Portfolio Transfer agreement with French insurer Wakam. Initially completed in 2025, the original deal covered approximately €140 million of reserves as at 31 December 2024, focusing mainly on UK and French motor and property insurance liabilities for 2024 and prior. The renewed LPT covers €126.5 million of net undiscounted reserves as at 31 December 2025, with a further accident year added to the reinsurance coverage under the parties' annual renewal framework. This agreement offers Wakam ongoing access to Compre's specialised capital solutions and legacy expertise, highlighting the flexibility of the Renewable LPT structure, an how it can evolve alongside client needs. The transaction is the first renewal under the Renewable LPT mechanism, representing an important evolution in Compre's reinsurance proposition while demonstrating its ability to deliver tailored solutions in an ongoing partnership. Will Bridger, CEO of Compre, said: "Renewing its agreement with Wakam is further progress for Compre and a strong endorsement of its ability to deliver capital and liability solutions that meet the evolving needs of its clients. "The addition of a further accident year under our annual renewal framework demonstrates the value of the partnership we have built with Wakam. We look forward to continuing to build on this relationship and to further developing our reinsurance offering." Catherine Charrier-Leflaive, Group CEO of Wakam, said: "Renewing with Compre turns a transaction into a partnership. Adding a further accident year under the annual framework keeps its balance sheet clean and its capital and teams focused on what matters most: scaling its Play & Plug(R) platform for its distribution partners across Europe. "This first renewal proves the structure is repeatable - smart capital management, year after year, clearing the path for Wakam to build the insurance infrastructure of tomorrow." The renewal further reinforces Compre's position as a specialist partner for insurers aiming to actively manage legacy liabilities and optimise capital. Delivering solutions across the risk lifecycle, the renewal underscores the structural repeatability of this framework and reflects strong confidence in Compre's capacity to deliver tailored solutions in this ongoing partnership.

Wakam commits to precision psychiatry: €250,000 to transform mental health. On 13 April 2026 in London, Wakam will present the first Precision Mind Prize, worth €250,000, in partnership with the FondaMental Foundation. This investment in Franco-British research on psychiatric biomarkers illustrates how insurance can play an active role in reducing one of the sector's most costly and least understood risks. Mental health: the underestimated risk weighing heavily on the bottom line Mental health disorders now represent one of the most dynamic claims areas for insurers: the leading cause of long-term sick leave in Europe, a growing driver of disability claims and income protection benefits, and an aggravating factor in many chronic conditions covered by supplemental health insurance. Yet unlike cancer or cardiovascular disease, psychiatry remains a field without validated biological markers. No objective tool for early diagnosis, no reliable criteria for risk stratification, no personalised treatment to reduce claims duration. For insurers, this makes it a risk that is difficult to model, and therefore difficult to manage. This is precisely the scientific barrier that Wakam has chosen to help break down. The Precision Mind Prize: a bet on transforming psychiatric risk Wakam, in partnership with the FondaMental Foundation, is launching the Precision Mind Prize: a €250,000 endowment designed to fund a collaborative Franco-British research project on psychiatric biomarkers. These biological indicators - blood based, neuroimaging, or digital - are the key to transforming psychiatry into a precision medicine discipline, much like what has already been achieved in oncology and cardiology. Supported projects aim to: * Diagnose earlier - detecting disorders before they worsen and generate lengthy, costly claims; * Personalise treatments - reducing the time to effective care, and therefore the duration of sick leave and disability; * Break the taboos around mental illness - destigmatising psychiatric conditions to improve their declaration and overall management. For the insurance sector, the implications are direct: a deeper understanding of biomarkers opens the door to finer risk modelling, better-calibrated income protection products, and more effective prevention policies. 13 April in London: the inaugural Precision Mind Prize ceremony The ceremony will take place in London on 13 April 2026. Olivier Jaillon, Chairman of the Board of the Wakam Group, will announce the winners, selected by a panel of Franco-British experts. The date and venue are no coincidence: they reflect Wakam's Franco-British roots - present across continental Europe and the United Kingdom - and its ambition to build an international scientific partnership commensurate with the challenges ahead. Wakam: the insurer investing in upstream risk prevention This initiative is part of the Wakam for Good strategy, Wakam's endowment fund, and its purpose as a mission-driven company. It reflects a strong conviction: the insurer of the future cannot settle for managing claims. It must invest in the conditions that reduce the frequency and severity of the risks it covers. "Economic and social shifts are accelerating vulnerabilities. As insurers, we believe that innovation and progress must serve people. The Precision Mind Prize will accelerate research in precision mental health and pave the way for truly personalised medicine." Catherine Charrier-Leflaive, CEO of the Wakam Group and President of Wakam for Good "Beyond enabling better and more precise patient care, this research will contribute to destigmatisation by demonstrating that many mental illnesses are, in reality, physiological conditions." Olivier Jaillon, Chairman of the Board - Wakam Group "This prize aspires to be a true catalyst for Franco-British research in precision psychiatry. It invites researchers, start-ups, and companies to join forces to transform our understanding of mental illness." Marion Leboyer, CEO of the FondaMental Foundation